Key clinical point: HIV nucleic acid amplification testing should be routine before PrEP.
Major finding: Almost a third of patients who developed HIV while on PrEP had strains that were resistant to emtricitabine at time of diagnosis, compared with just 2% of those not on PrEP.
Study details: Review of 3,685 new HIV cases in New York.
Disclosures: There was no external funding, and the investigators didn’t have any disclosures.
Misra K et al. 2019 CROI, Abstract 107.